Dumisile Nkosi

MMV is a not-for-profit organization working through a product development partnership model to deliver a portfolio of accessible medicines with the power to treat, prevent and eliminate malaria. We close critical gaps in research, development and access – working “end-to-end” to expand the use of existing antimalarials and innovate new compounds to protect public health. This starts with women and children. It’s working. As of 2024, MMV-supported products have effectively treated an estimated 711 million people and saved around 17.4 million lives. However, with over a quarter of a billion malaria cases and 597,000 deaths reported in 2023, progress towards disease elimination has stalled. MMV is part of an ecosystem of partners determined to change this. Bringing public and private sector partners together, we pioneer new solutions that align with local and global health priorities and promote the equitable development of effective and affordable products that work to help end malaria and advance health for all.